Unseen Ischemic Symptoms Result in Poor Care

BY THERESE DROSTE

Contributing Writer

WASHINGTON — Myocardial infarction patients who lacked documented ischemic symptoms upon hospital admission received lower quality care, were issued fewer established therapies, and had significantly higher risk-adjusted, inhospital mortality than those with symptoms, Erik Schelbert, M.D., reported at a meeting sponsored by the American Heart Association.

There was significantly less use of aspirin, β -blockers, and reperfusion therapy in those without ischemic symptoms, who were also more likely to be women, non-white, and older than the symptomatic patients.

"Curiously, these trends continued until discharge," said Dr. Schelbert of the University of Iowa, Iowa City.

He presented data from the Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery

This is the first study to include patient interviews in order to link symptoms with outcomes; 'there is evidence of a significant breakdown in communication.'

(PREMIER) study, which enrolled 3,960 MI patients in 19 centers during January 2003 through June 2004.

Dr. Schelbert and his coinvestigators reviewed the charts of 3,825 patients, comparing Centers for Medicare

and Medicaid Services performance measures and in-hospital death data to learn whether ischemic symptoms were documented.

Trauma patients and those with acute GI bleeds, strokes, and hip fractures were excluded.

A subgroup of 2,480 patients was interviewed within 2 days of admission to get their point of view of what brought them to the hospital.

While data from other studies have shown that women, minorities, and older patients often don't show traditional symptoms for MI, this is the first study to include patient interviews in order to link symptoms with outcomes.

Overall, 6.2% of the 3,825 patients had no ischemic symptoms documented in their charts upon admission, but of those who were interviewed, 72% had at least one symptom that would be considered ischemic by current American Heart Association/American College of Cardiology guidelines.

The undocumented symptoms included shortness of breath (50%), chest pain (40%), and nausea (31%).

Although troponin assays confirmed myocardial damage in all patients, the disparities in care were found to persist through discharge.

"Because the lack of documented symptoms of MI and the following lesser-quality care were linked, we inferred that patients' symptoms were not recognized.

Clearly, most patients actually did have symptoms, as the interviews then showed," said Dr. Schelbert. It's possible that these patients had comorbidities that made a diagnosis of MI more difficult, he added.

Of those asymptomatic patients eligible during hospital admission, 85% received aspirin vs. 96% of those with symptoms, 64% received β -blockers within 24 hours vs. 85% of patients with symptoms, and 18% received reperfusion therapy vs. 71%

of patients with symptoms, all significant differences


At hospital discharge, patients without ischemic symptoms were less likely than patients with ischemic symptoms to receive aspirin (86% vs. 94%), β -blockers (80% vs. 89%), or ACE inhibitors (58% vs. 69%).

Asymptomatic patients also were less likely to receive statin therapy for secondary MI prevention at LDL cholesterol thresholds of 100 mg/dL (70% vs. 87%) or

70 mg/dL (61% vs. 84%). Unadjusted inhospital mortality rates were also higher in patients without ischemic symptoms (15% vs. 3%).

"There is evidence of a significant breakdown in communication, and patient symptoms are being missed. The cause of this needs further investigation," said Dr. Schelbert.

The study was funded by grants from the Agency for Healthcare Research and Quality and CVT Therapeutics.



UNLESS HE TESTS WITH ONETOUCH® ULTRA®.

The blues are in his blood. Fortunately, OneTouch® Ultra® requires so little that B.B. can also test on his arm® when he wants to save those sensitive fingers for what they do best. Either way, he'll get a less painful test** with results in just five seconds.

Less pain. Less blood. Less time. More compliance.

More info? Call 1-800-524-7226 or visit www.LifeScan.com.





*Recommended by Diabetologists, Endocrinologists, Diabetes Educators, and Pharmacists, PET Tracking Study, Fall 2002. † When testing on the arm, patients should read the owner's booklet and talk to their healthcare professional. **Allows for a less painful stick when used with OneTouch® UltraSoft® Adjustable Blood Sampler and OneTouch® UltraSoft® Lancets. © 2005 LifeScan, Inc. Milpitas, CA 95035 1/05 AW 058-882B